SHENZHEN NEPTUNUS BIOENGINEERING CO., LTD.

Shenzhen Neptunus Bioengineering Co., Ltd.

000078

CNE000000X95

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-07-11 pm EDT			5-day change	1st Jan Change
2.18 ^CNY	-0.46%		-0.46%	-30.57%

Apr. 29	Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 29	Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Shenzhen Neptunus Bioengineering Co., Ltd. Announces Dividend for the Quarter of 2017

January 02, 2018 at 09:32 am EST

Shenzhen Neptunus Bioengineering Co., Ltd. announced quarterly dividend of CNY 0.7000 per ten shares (tax included) for the quarter of 2017, at the extraordinary general meeting held on December 29, 2017.

Latest news about Shenzhen Neptunus Bioengineering Co., Ltd.

Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 29	CI
Neptunus Bioengineering to Build Smart Logistics Park for 298 Million Yuan	Apr. 25	MT
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29	CI
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
UK Output Weakness Adds to BOE's Challenge	23-08-23	DJ
Shenzhen Neptunus Bioengineering to Set Up 150 Million Yuan Medical Equipment Unit	23-08-16	MT
FTSE 100 Closes Down 1.4% on US Credit Rating -2-	23-08-02	DJ
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Sector Update: Tech Stocks Edging Higher by Wednesday Close	23-03-15	MT
Sector Update: Tech	23-03-15	MT
FinVolution's Shares Fall Wednesday as Citigroup Downgrade Follows Lower Q4 Non-GAAP Earnings, Net Revenue	23-03-15	MT
FinVolution Group's Q4 Non-GAAP Earnings Decline, Revenue Rises; CEO Steps Down; Annual Dividend Raised	23-03-15	MT
Sterling May Fall Vs Euro as ECB More Aggressive -2-	23-03-07	DJ
Shenzhen Neptunus Bioengineering Warns of Loss in 2022	23-02-01	MT
Sterling Could Turn Lower Vs Dollar After Recent Gains	23-01-23	DJ
Shenzhen Neptunus Bioengineering Co., Ltd. Announces Executive Appointments	22-11-01	CI
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
FTSE 100 Closed Up Amid Falling Gas Prices, US Inflation Hopes	22-09-12	DJ
FTSE 100 Rises as Traders Eye Key US Inflation Data	22-09-12	DJ
Bets Against Pound Rise Amid Fears Over UK Growth, Fiscal Policy	22-09-12	DJ
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-24	CI
Hongta Securities Chairman, Two Others Resign as H1 Profit Halves	22-07-26	MT
Sterling to Be Little Affected by UK Leadership Debate	22-07-25	DJ
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI

Chart Shenzhen Neptunus Bioengineering Co., Ltd.

Duration

Period

Chart Shenzhen Neptunus Bioengineering Co., Ltd.

More charts

Company Profile

Shenzhen Neptunus Bioengineering Co.,Ltd is a China-based company principally engaged in pharmaceutical and food manufacturing and pharmaceutical commercial distribution businesses. The Companyâs main products include anti-tumor products, cardiovascular drugs, marine drugs, respiratory drugs, anti-infective products and other pharmaceuticals, as well as healthcare products, health food and medical instrument. The Company distributes its products mainly in domestic market, with East China as its main market.

Sector

Pharmaceuticals

Calendar

2024-08-30 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
SHENZHEN NEPTUNUS BIOENGINEERING CO., LTD.	-30.57%	827M
MCKESSON CORPORATION	+24.55%	74.8B
CARDINAL HEALTH, INC.	-6.59%	22.92B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+14.17%	8.74B
SINOPHARM GROUP CO. LTD.	-2.89%	7.94B
HUADONG MEDICINE CO., LTD	-33.14%	6.69B
H. LUNDBECK A/S	+22.28%	5.66B
EBOS GROUP LIMITED	-4.28%	4.02B
MEDIPAL HOLDINGS CORPORATION	+12.80%	3.41B
CHINA NATIONAL MEDICINES CORPORATION LTD.	+6.92%	3.18B

Pharmaceuticals Wholesale